



Supplementary Information



D




SI Fig.1 Gating strategies for FACS experiments

a) Gating strategy to determine the percentage of divided CD3⁺ T cells after 3 and 6 days of MLR. Alive CD3⁺ single cell T cells were gated for division based on CTV staining.

b) Gating strategy to determine maximum IFN-γ production after 6 days of control MLR. Alive CD3⁺ single cell T cells were gated for IFN-γ expression.

c) Gating strategy of surface-stained melanoma patient derived PBMCs to determine pre-treatment T cell characteristics of responders and non-responders. Alive CD3⁺ T cells were gated for PD-1, CD4 and CD8 expression. CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells were subsequently gated for PD-1 expression.

d) Gating strategy of intracellular stained melanoma patient derived PBMCs to determine pre-treatment T cell characteristics of responders and non-responders. Alive CD3⁺ T cells were gated for CD4 and CD8 expression. CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells were subsequently gated for IFN-γ and GzmB expression.







SI Fig.2 IL-6 reduces IFN-γ secretion by T cells both in the absence and presence of PD-1 blockade *in vitro*

a) IFN-γ secretion measured by ELISA after 6 days of mixed lymphocyte reaction (MLR) with 50,000 mismatched T cells and 10,000 moDCs of control donors, untreated or PD-1 blockade treated (αPD1; 10 μg/ml). The MLR was exposed to medium (control, n=21) "Fig.1a", or 0.1 μg/ml IL-6 (n=8).


b) Data of SI Fig.2a expressed as fold changes of IFN-γ secretion between αPD1 treated and untreated cells, exposed to medium (control, n=21), or 0.1 μg/ml IL-6. Fold change = [IFN-γ] in αPD1 treated cells (SI Fig.2a) / [IFN-γ] in untreated cells (SI Fig.2a).

a-b) Experiments were performed in duplo per "n", which were averaged. Averages are plotted as boxplots with medians and interquartile ranges (IQR). Depicted significance was determined using paired T tests on Log transformed data.



SI Fig.3 Similar pre-treatment T cell characteristics in responders and non-responders

- a)** Ratio of alive CD4⁺/CD8⁺ within the CD3⁺ T cells in treatment-naïve PBMCs of clinical responders (n=12) and non-responders (n=10).
- b)** PD-1 expression as percentage of alive CD3⁺T cells, CD3⁺CD4⁺ or CD3⁺CD8⁺ T cells in treatment-naïve PBMCs of clinical responders (n=12) and non-responders (n=10).
- c-d)** 4 hour PMA/ionomycin stimulated PBMCs of clinical responders (n=12) and non-responders (n=10). Percentage IFN-γ⁺ (**c**) or Granzyme B (**d**) expression in alive CD3⁺ CD4⁺, and CD8⁺ T cells.
- a-d)** Data plotted as boxplots with medians and IQR. Significance determined with Mann-Whitney tests.
- e)** IFN-γ secretion measured by ELISA at day 6 after start of a MLR with treatment-naïve PBMCs of clinical responders (n=6) and non-responders (n=5), untreated or αCD3 treated (0.1 μg/ml). Experiments were performed in triplo per "n", and medians were calculated. Medians are plotted as boxplots with medians and IQR. Significance determined with T tests.
- f)** IFN-γ secretion measured by ELISA at day 6 after start of a MLR with PBMCs of control donors, untreated or PD-1 blockade treated (αPD1; 10 μg/ml). The MLR was exposed to medium (control), or 100 U/ml IFN-α (n=3). Experiments were performed in triplo per "n", and medians were calculated. Medians are plotted as floating bar with mean. Significance determined with Wilcoxon tests.



SI Fig.4 PD-1 expression on T cells does not correlate with αPD-1 induced IFN-γ secretion in an MLR

Correlation of percentage CD3⁺PD-1⁺T cells "SI Fig.3b" with IFN-γ secretion induced by PD-1 blockade "Fig.3b" of treatment-naïve PBMCs of clinical responders (n=12) and non-responders (n=10). Significance determined with simple linear regression.